Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of prosthetic joint infections (PJI). With this IND clearance, APT plans to initiate a Phase 1/2 trial of PhageBank™ in PJI in the first half of 2021 in collaboration with Mayo Clinic.